Should the concentration of vitamin D be measured in all patients with hypertension?

Journal of Clinical Hypertension

Volumn 12, Issue 3, 2010, Pages 149-152

  Boldo, Angela ^a   Campbell, Patrick ^a   Luthra, Pooja ^b   White, William B ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; COLECALCIFEROL; PLACEBO; VITAMIN D;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG HALF LIFE; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; NONHUMAN; PATIENT ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY; VITAMIN METABOLISM;

CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; MASS SCREENING; REFERENCE VALUES; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77950135065     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00246.x     Document Type: Editorial

References (25)

1. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004, 80(6 suppl):1678S-1688S.
2. Giovannucci E. Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 2009, 19:84-88.
3. Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 2008, 624:55-71.
4. Holick MF. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
5. Martins D, Wolf M, Pan D. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007, 167:1159-1165.
6. Forman JP, Giovannucci E, Holmes MD. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49:1063-1069.
7. Wang TJ, Pencina MJ, Booth SL. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
8. Thorn LM, Forsblom C, Wadèn J. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2009, 32:950-952.
9. Wilson PW, D'Agostino RB, Levy D. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
10. Danesh J, Lewington S, Thompson SG. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799-1809.
11. Boushey CJ, Beresford SA, Omenn GS. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
12. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997, 30(2 Pt 1):150-156.
13. Kunes J, Tremblay J, Bellavance F. Influence of environmental temperature on the blood pressure of hypertensive patients in Montreal. Am J Hypertens 1991, 4(5 Pt 1):422-426.
14. Scragg R, Sowers MF, Bell C. Serum 25-hydroxyvitamin D, ethnicity and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007, 20:713-719.
15. Li YC, Qiao G, Uskokovic M. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004, 89-90:387-392.
16. Li YC, Kong J, Wei M. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
17. Kong J, Qiao G, Zhang Z. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int 2008, 74:1577-1581.
18. Wong MS, Delansorne R, Man RY. Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008, 295:H289-H296.
19. Cardus A, Panizo S, Encinas M. 1,25-Dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009, 204:85-89.
20. Carthy EP, Yamashita W, Hsu A. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 1989, 13:954-959.
21. Sugden JA, Davies JI, Witham MD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008, 25:320-325.
22. Krause R, Bühring M, Hopfenmüller W. Ultraviolet B and blood pressure. Lancet 1998, 352:709-710.
23. Pfeifer M, Begerow B, Minne HW. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001, 86:1633-1637.
24. Lind L, Wengle B, Wide L. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status: a double-blind, placebo-controlled study. Am J Hypertens 1989, 2:20-25.
25. Holick MF. MrOs is D-ficient. J Clin Endocrinol Metab 2009, 94:1092-1093.